Form 4: Monopar Therapeutics CEO Chandler Robinson Reports Stock Transactions
SEC Form 4
Chandler Robinson, CEO of Monopar Therapeutics, reports the acquisition and disposal of common stock related to the vesting of restricted stock units.
Summary
- Chandler Robinson, the CEO of Monopar Therapeutics, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
- The reported transactions involve the vesting and settlement of restricted stock units (RSUs).
- On September 30, 2024, Robinson acquired 4,895 shares of common stock upon the vesting of RSUs.
- Also on September 30, 2024, 1,918 shares were withheld by the issuer to cover withholding taxes related to the RSU vesting at a price of $6.74.
- Following these transactions, Robinson directly owns 56,162 shares of common stock.
- Robinson also indirectly controls 822,255 shares through Tactic Pharma LLC, and directly owns 33,334 shares through Tactic Pharma LLC.
- The reported transactions reflect adjustments for a 5-for-1 reverse stock split that occurred on August 12, 2024.
- The RSUs were granted in tranches in January 2021, February 2022 and February 2023, vesting quarterly.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Positives
- The vesting of RSUs suggests that the CEO is meeting certain performance milestones.
Industry Context
Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.
Comparison to Industry Standards
- Similar insider transactions are common in the pharmaceutical industry, where stock options and RSUs are frequently used as part of executive compensation packages.
- Comparing the vesting schedules and amounts of RSUs to those of peer companies like Mustang Bio or Oncolytics Biotech could provide context on the competitiveness of Monopar's executive compensation.
Stakeholder Impact
- The transactions have a minor impact on shareholders, as they reflect the standard vesting of executive compensation.
- Employees holding RSUs are positively impacted as their units vest into shares.
Key Dates
| Date | Description |
|---|---|
| January 26, 2021 | Reporting person was granted 12,612 restricted stock units, vesting 6/48ths (1,577 shares) on June 30, 2021, and 3/48ths (788 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. |
| February 2, 2022 | Reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. |
| February 1, 2023 | Reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. |
| August 12, 2024 | Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock. |
| September 30, 2024 | CEO Chandler Robinson acquired 4,895 shares of Monopar Therapeutics common stock upon vesting of restricted stock units; 1,918 shares were withheld by the issuer for tax obligations at $6.74 per share. |
| October 02, 2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.